Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Y.K. Binder is active.

Publication


Featured researches published by Bernard Y.K. Binder.


PLOS ONE | 2012

Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells.

Allison I. Hoch; Bernard Y.K. Binder; Damian C. Genetos; J. Kent Leach

Mesenchymal stem cells (MSCs) are a promising cell population for cell-based bone repair due to their proliferative potential, ability to differentiate into bone-forming osteoblasts, and their secretion of potent trophic factors that stimulate angiogenesis and neovascularization. To promote bone healing, autogenous or allogeneic MSCs are transplanted into bone defects after differentiation to varying degrees down the osteogenic lineage. However, the contribution of the stage of osteogenic differentiation upon angiogenic factor secretion is unclear. We hypothesized that the proangiogenic potential of MSCs was dependent upon their stage of osteogenic differentiation. After 7 days of culture, we observed the greatest osteogenic differentiation of MSCs when cells were cultured with dexamethasone (OM+). Conversely, VEGF protein secretion and upregulation of angiogenic genes were greatest in MSCs cultured in growth media (GM). Using conditioned media from MSCs in each culture condition, GM-conditioned media maximized proliferation and enhanced chemotactic migration and tubule formation of endothelial colony forming cells (ECFCs). The addition of a neutralizing VEGF165/121 antibody to conditioned media attenuated ECFC proliferation and chemotactic migration. ECFCs seeded on microcarrier beads and co-cultured with MSCs previously cultured in GM in a fibrin gel exhibited superior sprouting compared to MSCs previously cultured in OM+. These results confirm that MSCs induced farther down the osteogenic lineage possess reduced proangiogenic potential, thereby providing important findings for consideration when using MSCs for bone repair.


Stem Cells Translational Medicine | 2016

Increased Survival and Function of Mesenchymal Stem Cell Spheroids Entrapped in Instructive Alginate Hydrogels

Steve S. Ho; Kaitlin C. Murphy; Bernard Y.K. Binder; Caroline B. Vissers; J. Kent Leach

Mesenchymal stem cell (MSC)‐based therapies are under broad investigation for applications in tissue repair but suffer from poor cell persistence and engraftment upon transplantation. MSC spheroids exhibit improved survival, anti‐inflammatory, and angiogenic potential in vitro, while also promoting vascularization when implanted in vivo. However, these benefits are lost once cells engage the tissue extracellular matrix and migrate from the aggregate. The efficacy of cell therapy is consistently improved when using engineered materials, motivating the need to investigate the role of biomaterials to instruct spheroid function. In order to assess the contribution of adhesivity on spheroid activity in engineered materials and promote the bone‐forming potential of MSCs, we compared the function of MSC spheroids when entrapped in Arg‐Gly‐Asp (RGD)‐modified alginate hydrogels to nonfouling unmodified alginate. Regardless of material, MSC spheroids exhibited reduced caspase activity and greater vascular endothelial growth factor (VEGF) secretion compared with equal numbers of dissociated cells. MSC spheroids in RGD‐modified hydrogels demonstrated significantly greater cell survival than spheroids in unmodified alginate. After 5 days in culture, spheroids in RGD‐modified gels had similar levels of apoptosis, but more than a twofold increase in VEGF secretion compared with spheroids in unmodified gels. All gels contained mineralized tissue 8 weeks after subcutaneous implantation, and cells entrapped in RGD‐modified alginate exhibited greater mineralization versus cells in unmodified gels. Immunohistochemistry confirmed more diffuse osteocalcin staining in gels containing spheroids compared with dissociated controls. This study demonstrates the promise of cell‐instructive biomaterials to direct survival and function of MSC spheroids for bone tissue engineering applications.


Scientific Reports | 2013

Systematic repression of transcription factors reveals limited patterns of gene expression changes in ES cells

Akira Nishiyama; Alexei A. Sharov; Yulan Piao; Misa Amano; Tomokazu Amano; Hien G. Hoang; Bernard Y.K. Binder; Richard Tapnio; Uwem C. Bassey; Justin N. Malinou; Lina S. Correa-Cerro; Hong Yu; Li Xin; Emily Meyers; Michal Zalzman; Yuhki Nakatake; Carole A. Stagg; Lioudmila V. Sharova; Yong Qian; Dawood B. Dudekula; Sarah Sheer; Jean S. Cadet; Tetsuya Hirata; Hsih Te Yang; Ilya G. Goldberg; Michele K. Evans; Dan L. Longo; David Schlessinger; Minoru S.H. Ko

Networks of transcription factors (TFs) are thought to determine and maintain the identity of cells. Here we systematically repressed each of 100 TFs with shRNA and carried out global gene expression profiling in mouse embryonic stem (ES) cells. Unexpectedly, only the repression of a handful of TFs significantly affected transcriptomes, which changed in two directions/trajectories: one trajectory by the repression of either Pou5f1 or Sox2; the other trajectory by the repression of either Esrrb, Sall4, Nanog, or Tcfap4. The data suggest that the trajectories of gene expression change are already preconfigured by the gene regulatory network and roughly correspond to extraembryonic and embryonic fates of cell differentiation, respectively. These data also indicate the robustness of the pluripotency gene network, as the transient repression of most TFs did not alter the transcriptomes.


Acta Biomaterialia | 2014

Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogels.

Soumia Jose; Marissa L. Hughbanks; Bernard Y.K. Binder; Ganesh C. Ingavle; J. Kent Leach

Recombinant proteins and cytokines are under broad preclinical and clinical investigation to promote angiogenesis, but their success is limited by ineffective delivery, lack of long-term stability and excessive cost. Mesenchymal stem/stromal cells (MSC) secrete bioactive trophic factors, and thus, may provide an effective alternative to address these challenges. Glycine-Histidine-Lysine (GHK) is a peptide fragment of osteonectin, a matricellular protein with reported proangiogenic potential. We examined the capacity of GHK to up-regulate secretion of proangiogenic factors from human MSC in culture and when covalently coupled to alginate hydrogels. GHK had no apparent cytotoxic effects on MSC in culture over a wide range of concentrations. We detected a dose-dependent increase in vascular endothelial growth factor (VEGF) concentration in media conditioned by GHK-treated MSC, which increased endothelial cell proliferation, migration and tubule formation. We covalently coupled GHK to alginate using carbodiimide chemistry, and human MSC were entrapped in alginate hydrogels to assess VEGF secretion. Similar to monolayer culture, MSC responded to GHK-modified gels by secreting increased concentrations of VEGF and basic fibroblast growth factor compared to unmodified gels. The pre-treatment of MSC with antibodies to α6 and β1 integrins prior to entrapment in GHK-modified gels abrogated VEGF secretion, suggesting that the proangiogenic response of MSC was integrin-mediated. These data demonstrate that the proangiogenic potential of MSC can be significantly increased by the presentation of GHK with a biodegradable carrier, therefore increasing their clinical potential when used for tissue repair.


Scientific Reports | 2011

Generation of mouse ES cell lines engineered for the forced induction of transcription factors

Lina S. Correa-Cerro; Yulan Piao; Alexei A. Sharov; Akira Nishiyama; Jean S. Cadet; Hong Yu; Lioudmila V. Sharova; Li Xin; Hien G. Hoang; Marshall Thomas; Yong Qian; Dawood B. Dudekula; Emily Meyers; Bernard Y.K. Binder; Gregory Mowrer; Uwem C. Bassey; Dan L. Longo; David Schlessinger; Minoru S.H. Ko

Here we report the generation and characterization of 84 mouse ES cell lines with doxycycline-controllable transcription factors (TFs) which, together with the previous 53 lines, cover 7–10% of all TFs encoded in the mouse genome. Global gene expression profiles of all 137 lines after the induction of TFs for 48 hrs can associate each TF with the direction of ES cell differentiation, regulatory pathways, and mouse phenotypes. These cell lines and microarray data provide building blocks for a variety of future biomedical research applications as a community resource.


PLOS ONE | 2013

Lysophosphatidic Acid Enhances Stromal Cell-Directed Angiogenesis

Bernard Y.K. Binder; Claus Sondergaard; Jan A. Nolta; J. Kent Leach

Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.


Scientific Reports | 2017

Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by Resveratrol

Yichen Zhu; Toshio Takayama; Bowen Wang; Alycia Kent; Mengxue Zhang; Bernard Y.K. Binder; Go Urabe; Yatao Shi; Daniel DiRenzo; Shakti A. Goel; Yifan Zhou; Christopher B. Little; Drew A. Roenneburg; Xu Dong Shi; Lingjun Li; William L. Murphy; K. Craig Kent; Jianjuan Ke; Lian-Wang Guo

To date, there is no periadventitial drug delivery method available in the clinic to prevent restenotic failure of open vascular reconstructions. Resveratrol is a promising anti-restenotic natural drug but subject to low bioavailability when systemically administered. In order to reconcile these two prominent issues, we tested effects of periadventitial delivery of resveratrol on all three major pro-restenotic pathologies including intimal hyperplasia (IH), endothelium impairment, and vessel shrinkage. In a rat carotid injury model, periadventitial delivery of resveratrol either via Pluronic gel (2-week), or polymer sheath (3-month), effectively reduced IH without causing endothelium impairment and vessel shrinkage. In an in vitro model, primary smooth muscle cells (SMCs) were stimulated with elevated transforming growth factor (TGFβ) and its signaling protein Smad3, known contributors to IH. TGFβ/Smad3 up-regulated Kruppel-like factor (KLF5) protein, and SMC de-differentiation which was reversed by KLF5 siRNA. Furthermore, TGFβ/Smad3-stimulated KLF5 production and SMC de-differentiation were blocked by resveratrol via its inhibition of the Akt-mTOR pathway. Concordantly, resveratrol attenuated Akt phosphorylation in injured arteries. Taken together, periadventitial delivery of resveratrol produces durable inhibition of all three pro-restenotic pathologies — a rare feat among existing anti-restenotic methods. Our study suggests a potential anti-restenotic modality of resveratrol application suitable for open surgery.


Tissue Engineering Part A | 2012

Cell-Derived Matrix Coatings for Polymeric Scaffolds

Martin L. Decaris; Bernard Y.K. Binder; Matthew A. Soicher; Archana Bhat; J. Kent Leach


Tissue Engineering Part A | 2014

Lysophosphatidic acid protects human mesenchymal stromal cells from differentiation-dependent vulnerability to apoptosis

Bernard Y.K. Binder; Damian C. Genetos; J. Kent Leach


Tissue Engineering Part A | 2013

Enhancing Osteoconductivity of Fibrin Gels with Apatite-Coated Polymer Microspheres

Hillary E. Davis; Bernard Y.K. Binder; Phillip Schaecher; Dana D. Yakoobinsky; Archana Bhat; J. Kent Leach

Collaboration


Dive into the Bernard Y.K. Binder's collaboration.

Top Co-Authors

Avatar

J. Kent Leach

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alexei A. Sharov

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Archana Bhat

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dan L. Longo

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David Schlessinger

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Dawood B. Dudekula

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge